The Government receives some proposals of Asebio to enrich the Plan Profarma
18 September 2013
The Spanish Association of Bioempresas (
During SAW it Annual Conference of the Technological Platforms of Investigation Biomédica: ‘Innovative Medicines, Nanomedicina, Sanitary ware Technology and Markets Biotecnológicos' celebrated in March in Madrid, the president of Asebio, Regina Revilla, did a call to the Government so that it reviewed the Plan Profarma with the aim that the sector biotecnológico had greater weight.
The BOE finishes to publish the announcement of the Plan Profarma that goes headed to the companies of the pharmaceutical sector, situated in Spain, that manufacture or commercialise medicines of human use and that realizar activities of pharmaceutical R&D in the national territory. This program has like fundamental aim increase the competitiveness of the pharmaceutical industry in Spain, through the modernisation of the sector and the potenciación of those activities that contribute a greater value added.
Asebio Has kept diverse meetings with the Executive with the aim that the Plan Profarma will adapt more to the reality of the sector biotecnológico Spanish. Like novelties, on request of Asebio, will evaluate the realisation of clinical essays in Spain, particularly in the earliest phases and the costs in R&D.
This measure is especially notable for Asebio, since there is a big number of companies biotecnológicas initiating the clinical development of his molecules.
![Imagen](https://img.interempresas.net/fotos/880958.jpeg)
This year, includes a classification of the companies in these groups:
Group To: Companies with activity significant researcher with own plant of pharmaceutical production or centre typical of basic R&D or preclínica.
Group B: Companies with own plant of pharmaceutical production and that realizar some activities of R&D, like technological development, but do not reach the level of significant.
Group C: Companies without plant of pharmaceutical production but with activity of own R&D or hired in national territory.
The companies that do not reach the minimum punctuation that establishes the Committee of Coordination to be described, will be considered ‘no valued'.